Literature DB >> 26016932

Tissue content of sulfomucins and sialomucins in the colonic mucosa, without fecal stream, undergoing daily intervention with sucralfate.

Christiny Emmanuelle Gabriel Bonassa1, José Aires Pereira2, Fábio Guilherme Caserta Maryssael de Campos3, Murilo Rocha Rodrigues4, Daniela Tiemi Sato4, Felipe David Mendonça Chaim1, Carlos Augusto Real Martinez2.   

Abstract

PURPOSE: To measure the content of acidic mucin, sialomucin, and sulfomucins in the colonic mucosa without fecal stream submit to intervention with sucralfate (SCF).
METHODS: Thirty-six rats were submitted to a right colostomy and a distal mucous fistula and divided into two groups according to sacrifice to be performed two or four weeks. Each group was divided into three subgroups according daily application of enemas containing saline, SCF at 1.0 g/kg/day or 2.0 g/kg/day. Colitis was diagnosed by histological analysis. Acid mucins were determined with the Alcian-Blue and sulfomucin and sialomucin by high iron diamine-alcian blue (HID-AB) techniques. The mucins were quantified by computer-assisted image analysis. Mann-Whitney and ANOVA tests were used to analyze the results establishing the level of significance of 5% for both (p<0.05).
RESULTS: SCF enemas decreased the inflammation score and was related to the concentration used and time of the intervention. SCF at both concentrations increased the content of acid mucin, which was related to the concentration used and to the improvement in the inflammatory score. There was an increase in the content of sulfomucins and sialomucins in SCF groups. SCF increased sulfomucins from 2 weeks of intervention, which was not related to the dose or time of application. The increase in sialomucin content was related to the time and dose used in the intervention.
CONCLUSION: Sucralfate increased the content of acidic mucins, primarily at the expense of sialomucin, which was affected by the dose and time of intervention.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26016932     DOI: 10.1590/S0102-865020150050000004

Source DB:  PubMed          Journal:  Acta Cir Bras        ISSN: 0102-8650            Impact factor:   1.388


  5 in total

Review 1.  Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives.

Authors:  Suresh P Sulochana; Muzeeb Syed; Devaraj V Chandrasekar; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

2.  EVALUATION OF ENEMAS CONTAINING SUCRALFATE IN TISSUE CONTENT OF MUC-2 PROTEIN IN EXPERIMENTAL MODEL OF DIVERSION COLITIS.

Authors:  Oscar Orlando Araya Fernandez; José Aires Pereira; Fábio Guilherme Campos; Carolina Mardegan Araya; Gabriele Escocia Marinho; Rafaela de Souza Novo; Thais Silva de Oliveira; Yara Tinoco Franceschi; Carlos Augusto Real Martinez
Journal:  Arq Bras Cir Dig       Date:  2017 Apr-Jun

3.  EVALUATION OF ENEMAS CONTAINING SUCRALFATE IN TISSUE CONTENT OF MUC-2 PROTEIN IN EXPERIMENTAL MODEL OF DIVERSION COLITIS.

Authors:  Oscar Orlando Araya Fernandez; José Aires Pereira; Fábio Guilherme Campos; Carolina Mardegan Araya; Gabriele Escocia Marinho; Rafaela de Souza Novo; Thais Silva de Oliveira; Yara Tinoco Franceschi; Carlos Augusto Real Martinez
Journal:  Arq Bras Cir Dig       Date:  2018-08-16

4.  Sucralfate enemas reduce the oxidative tissue damage and preserves the contents of E-cadherin and ?-catenin in colonic mucosa without fecal stream.

Authors:  Daniela Tiemi Sato; Fabio Guilherme Campos; Paulo Gustavo Kotze; Roberta Laís Santos Mendonça; Danilo Toshio Kanno; José Aires Pereira; Carlos Augusto Real Martinez
Journal:  Acta Cir Bras       Date:  2021-11-29       Impact factor: 1.388

5.  CAN SUCRALFATE ENEMA PREVENT COLITIS IN COLONIC SEGMENTS WITHOUT FECAL TRANSIT?

Authors:  Roberta Laís Silva Mendonça; Danilo Toshio Kanno; José Aires Pereira; Fabio Guilherme Campos; Camila Morais Gonçalves da Silva; Bruna Zini de Paula Freitas; Carlos Augusto Real Martinez
Journal:  Arq Bras Cir Dig       Date:  2022-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.